繁
简
Market+ (iPhone)
Market+ (Android)
Mobile Site
US STOCKS
FUNDS
FX & CRYPTO
SH/SZ-HK
HK STOCKS
 
 
 
 
 
 
Quote Service
Market
Market
Quotes
Quotes
Analysis
Analysis
Commentary
Commentary
Warrants&CBBCs
Warrants&CBBCs
Warrants&CBBCs Overview
Warrants
CBBCs
ETF
ETF
MPF
MPF
Education
Members
Members
About Us
About Us

ETF Overview

TRACKER FUND
ISHARES A50
HSCEI ETF
CSOP A50 ETF
CAM CSI300
Last (HKD)1
Details»
Vol. 
Turn. 
Range
NAV (HKD)
Premium%
1-Month Range
2-Month Range
3-Month Range
52-Week Range
1D
1M
Advanced Chart
ETF Overview
Issuer
Expenses & Facts
Analysis
Calendar Yr Chg
Cumulative Chg
Overview (By Turn.)
Overview (By Asset)
Name/ Symbol
Underlying Asset
Last1
Chg
Chg%
Vol.
Turn.
NAV (Premium%)
Chart
Compare
TRACKER FUND
 Hang Seng Index 24.760
 HKD 		-0.140 -0.562% 296.37M 7.34B 23.260 (+6.450%)
HKD as at 2025/02/25
HSCEI ETF
 Hang Seng China Enterprises 91.140
 HKD 		-0.580 -0.632% 66.63M 6.07B 86.975 (+4.788%)
HKD as at 2025/02/25
CSOP HS TECH
 Hang Seng TECH Index 5.255
 HKD 		0.000 0.000% 976.99M 5.13B 5.580 (-5.828%)
HKD as at 2025/02/25
XL2CSOPHSTECH
+2x
Leveraged Products typically aim to deliver a daily return equivalent to a multiple of the underlying index return that they track. Leveraged Products seeking SFC authorisation shall be subject to a maximum leverage factor of two times (2x).
 Hang Seng TECH Index 5.185
 HKD 		-0.020 -0.384% 160.47M 832.27M 6.590 (-21.320%)
HKD as at 2025/02/25
XI2CSOPHSTECH
-2x
Inverse Products typically aim to deliver the opposite of the daily return of the underlying index that they track. Inverse Products seeking SFC authorisation shall be subject to a maximum leverage factor of one time (-1x); Inverse Products cannot be leveraged.
 Hang Seng TECH Index 1.700
 HKD 		+0.012 +0.711% 376.39M 637.93M 1.831 (-7.175%)
HKD as at 2025/02/25
FI2 CSOP HSI
-2x
Inverse Products typically aim to deliver the opposite of the daily return of the underlying index that they track. Inverse Products seeking SFC authorisation shall be subject to a maximum leverage factor of one time (-1x); Inverse Products cannot be leveraged.
 Hang Seng Index 2.162
 HKD 		+0.028 +1.312% 125.34M 271.11M 2.726 (-20.687%)
HKD as at 2025/02/25
ISHARESHSTECH
 Hang Seng TECH Index 11.230
 HKD 		-0.040 -0.355% 18.42M 207.17M 12.133 (-7.440%)
HKD as at 2025/02/24
FL2 CSOP HSI
+2x
Leveraged Products typically aim to deliver a daily return equivalent to a multiple of the underlying index return that they track. Leveraged Products seeking SFC authorisation shall be subject to a maximum leverage factor of two times (2x).
 Hang Seng Index 5.410
 HKD 		-0.060 -1.097% 36.69M 198.41M 5.000 (+8.206%)
HKD as at 2025/02/25
ISHARES A50
 FTSE China A50 14.510
 HKD 		+0.020 +0.138% 12.43M 180.40M 13.749 (+5.535%)
HKD as at 2025/02/24
A GX HSCEICC
 Hang Seng China Enterprises 10.720
 HKD 		+0.010 +0.093% 7.73M 82.77M 10.808 (-0.817%)
HKD as at 2025/02/24
CAM HSI ESG
 HSI ESG Enhanced Index (net total return index) 51.040
 HKD 		-0.560 -1.085% 1.35M 68.95M 47.751 (+6.887%)
HKD as at 2025/02/25
HSTECH ETF
 Hang Seng TECH Index 5.320
 HKD 		-0.025 -0.468% 12.12M 64.58M 5.659 (-5.982%)
HKD as at 2025/02/25
CAM CSI300
 CSI 300 44.900
 HKD 		+0.040 +0.089% 1.29M 58.15M 43.473 (+3.282%)
HKD as at 2025/02/25
CSOP A50 ETF
 FTSE China A50 13.520
 HKD 		+0.020 +0.148% 3.35M 45.29M 12.681 (+6.614%)
HKD as at 2025/02/25
SPDR GOLD TRT
 London Gold Fixing Price 2,418.000
 HKD 		+10.000 +0.415% 12.32K 29.75M N/A
FI2CSOPNASDAQ
-2x
Inverse Products typically aim to deliver the opposite of the daily return of the underlying index that they track. Inverse Products seeking SFC authorisation shall be subject to a maximum leverage factor of one time (-1x); Inverse Products cannot be leveraged.
 NASDAQ-100 Index 4.154
 HKD 		-0.042 -1.001% 5.13M 21.38M 4.925 (-15.660%)
HKD as at 2025/02/24
CAM HSBIOTECH
 Hang Seng Hong Kong-Listed Biotech Index 13.480
 HKD 		-0.270 -1.964% 1.38M 18.61M 10.297 (+30.909%)
HKD as at 2025/02/25
FL2CSOPGOLD
+2x
Leveraged Products typically aim to deliver a daily return equivalent to a multiple of the underlying index return that they track. Leveraged Products seeking SFC authorisation shall be subject to a maximum leverage factor of two times (2x).
 Solactive Gold 1-Day Rolling Futures Index 17.150
 HKD 		+0.140 +0.823% 996.20K 17.01M 13.980 (+22.679%)
HKD as at 2025/02/24
A CSOP USD MM-U
 FTSE 3-Month US Dollar Eurodeposit Index 118.400
 USD 		+0.050 +0.042% 141.72K 16.78M 116.777 (+1.390%)
USD as at 2025/02/25
FI2CAMNDQ100
-2x
Inverse Products typically aim to deliver the opposite of the daily return of the underlying index that they track. Inverse Products seeking SFC authorisation shall be subject to a maximum leverage factor of one time (-1x); Inverse Products cannot be leveraged.
 NASDAQ-100 Index 0.632
 HKD 		-0.008 -1.250% 24.07M 15.29M 0.748 (-15.463%)
HKD as at 2025/02/24
GX HS HIGH DIV
 Hang Seng High Dividend Yield 28.220
 HKD 		-0.020 -0.071% 520.90K 14.69M 24.714 (+14.186%)
HKD as at 2025/02/24
XL2CSOPCSI300
+2x
Leveraged Products typically aim to deliver a daily return equivalent to a multiple of the underlying index return that they track. Leveraged Products seeking SFC authorisation shall be subject to a maximum leverage factor of two times (2x).
 CSI 300 3.680
 HKD 		-0.020 -0.541% 3.65M 13.46M 3.748 (-1.825%)
HKD as at 2025/02/25
GX CN ROBO&AI
 FactSet China Robotics and Artificial Intelligence Index (net total return) 46.520
 HKD 		-0.080 -0.172% 285.49K 13.43M 54.860 (-15.202%)
HKD as at 2025/02/24
FI CSOP HSI
-1x
Inverse Products typically aim to deliver the opposite of the daily return of the underlying index that they track. Inverse Products seeking SFC authorisation shall be subject to a maximum leverage factor of one time (-1x); Inverse Products cannot be leveraged.
 Hang Seng Index 3.708
 HKD 		+0.028 +0.761% 2.65M 9.84M 4.098 (-9.526%)
HKD as at 2025/02/25
CAM BTC
 CME CF Bitcoin Reference Rate- Asia Pacific Variant 13.420
 HKD 		+0.190 +1.436% 692.20K 9.25M 11.063 (+21.307%)
HKD as at 2025/02/25
XL2 BOS CHINEXT
+2x
Leveraged Products typically aim to deliver a daily return equivalent to a multiple of the underlying index return that they track. Leveraged Products seeking SFC authorisation shall be subject to a maximum leverage factor of two times (2x).
 ChiNext Index (HKD)(CNH) 3.670
 HKD 		-0.058 -1.556% 2.21M 8.24M 4.284 (-14.336%)
HKD as at 2025/02/24
CAM CSI300-R
 CSI 300 40.980
 CNY 		-0.120 -0.292% 175.40K 7.19M 40.598 (+0.940%)
CNY as at 2025/02/25
FL2 CSOP HSCEI
+2x
Leveraged Products typically aim to deliver a daily return equivalent to a multiple of the underlying index return that they track. Leveraged Products seeking SFC authorisation shall be subject to a maximum leverage factor of two times (2x).
 Hang Seng China Enterprises 3.358
 HKD 		-0.044 -1.293% 2.01M 6.76M 3.260 (+3.022%)
HKD as at 2025/02/25
PING AN HKDIV
 CSI Hong Kong Dividend 36.700
 HKD 		0.000 0.000% 181.00K 6.65M 32.341 (+13.478%)
HKD as at 2025/02/25
CSOP STAR 50
 SSE Science and Technology Innovation Board 50 Index 9.190
 HKD 		-0.050 -0.541% 709.90K 6.56M 10.021 (-8.290%)
HKD as at 2025/02/25
(1) All quotes for Hong Kong Stocks are at least 15 minutes delayed. Last Updated: 2025/06/26 16:08
 
SITEMAP
AASTOCKS.com
 
 
Members
 
About Us
Market
Quotes
 
Analysis
News & Research
 
Commentary
 
Warrants&CBBCs
 
Warrants
 
CBBCs
 
US Stocks
Forex
 
Fund
 
MPF
Email: support@aastocks.com
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.
Disclaimer
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司), HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

The above is strictly for information purposes only and should not be considered an offer, or solicitation, to deal in any of the mentioned funds. Investment involves risk, emerging markets may have greater risk than developed markets. Subscriptions may only be made on the basis of the relevant offering documents, most recent annual financial statement and semi-annual financial statements if published thereafter. The value of investments and the income received from them (if any) may be volatile and could change substantially within a short period of time. Past performance is not a guide to future performance. The investment returns are denominated in the base currency of the fund. US dollar / HK dollar based investors are therefore exposed to fluctuations in the US dollar / HK dollar / base currency exchange rate.

BEFORE MAKING AN INVESTMENT, YOU SHOULD REFER TO THE RELEVANT OFFERING DOCUMENTS AND IN PARTICULAR TO THE INVESTMENT POLICIES AND THE RISK FACTORS. YOU SHOULD ENSURE THAT YOU FULLY UNDERSTAND THE RISKS ASSOCIATED WITH THE FUND AND SHOULD ALSO CONSIDER YOUR OWN INVESTMENT OBJECTIVE AND RISK TOLERANCE LEVEL. YOU ARE REMINDED THAT YOU ARE RESPONSIBLE FOR YOUR INVESTMENT DECISION AND SHOULD NOT INVEST UNLESS THE INTERMEDIARY WHO OFFERS OR SELLS THE FUND TO YOU HAS ADVISED THAT THE FUND IS SUITABLE FOR YOU AND HAS EXPLAINED WHY, INCLUDING HOW BUYING THE FUND WOULD BE CONSISTENT WITH YOUR INVESTMENT OBJECTIVE. IF IN DOUBT, PLEASE SEEK INDEPENDENT FINANCIAL AND PROFESSIONAL ADVICE.

The information and products contained within this website are restricted to investors within Hong Kong. There are important legal and regulatory restrictions which apply to this website. These are laid out in the Disclaimer section which you are advised to read before proceeding. By proceeding, you are representing that you have understood and accepted the restrictions set out in the Disclaimer section.

Third party websites provided by hyperlinks on this website are completely beyond the control of AASTOCKS. Accordingly, AASTOCKS accepts no responsibility for the accuracy, completeness and legality of the contents of such third party website, or for any offers, services and products contained therein.

Remarks: All HK and China Indices are real time. World indices are at least 30 – 60 minutes delayed.
 
 
 
ETF Comparison
1
2
Compare